- Home
- GOF vs APLS Comparison
GOF vs APLS Comparison
Compare GOF & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GOF | APLS |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2006 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GOF | APLS |
|---|---|---|
| Price | $11.22 | $40.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $31.47 |
| AVG Volume (30 Days) | 1.6M | ★ 5.0M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.21 |
| P/E Ratio | ★ N/A | $201.23 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $10.54 | $16.10 |
| 52 Week High | $15.44 | $40.45 |
Technical Indicators
Market Signals| Indicator | GOF | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 48.51 | 87.60 |
| Support Level | N/A | $19.38 |
| Resistance Level | $15.13 | N/A |
| Average True Range (ATR) | 0.19 | 0.57 |
| MACD | 0.05 | 2.34 |
| Stochastic Oscillator | 91.45 | 99.72 |
Price Performance
Historical ComparisonAbout GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).